Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind parallel-group phase 3 study of higher-dose dulaglutide added to metformin in adults with type 2 diabetes mellitus
MOH_2018-03-15_002073Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in glycated hemoglobin. Started Mar 2018; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2018-03-15_002073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-15_002073.